Because of the recognized contributions of dyslipidemia and inflammation to insulin resistance, we sought to test if TKI-mediated inhibition of RIPK2 could attenuate NOD1-induced impairments in insulin signalling in adipocytes. This evidence concerns the gene NOD1 and Insulin resistance.